Compare AISP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | AGEN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 126.2M |
| IPO Year | N/A | 1999 |
| Metric | AISP | AGEN |
|---|---|---|
| Price | $2.70 | $3.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | ★ 581.7K | 410.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $222.88 | $5.19 |
| Revenue Next Year | $5.36 | $68.25 |
| P/E Ratio | ★ $3.18 | $9.12 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.36 | $1.38 |
| 52 Week High | $7.20 | $7.34 |
| Indicator | AISP | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.96 | 53.30 |
| Support Level | $2.36 | $2.90 |
| Resistance Level | $3.92 | $4.72 |
| Average True Range (ATR) | 0.18 | 0.18 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 53.28 | 83.87 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).